london-biotech
(2)
Kevin Walton
Kevin Walton is the Chief Executive Officer and Board Director of Baseimmune, a London-based biotech using AI and computational protein design to build next-generation vaccines and active immunotherapies. He joined in 2024 after a career in biotech corporate development and dealmaking at Moderna, StrideBio, Curis and G1 Therapeutics, and is steering the company beyond infectious-disease vaccines into chronic diseases, starting with a lead fibrosis program in idiopathic pulmonary fibrosis.
Michael Shih
Michael Shih is the Chief Executive Officer of NeoPhore Ltd, a London-based small molecule neoantigen immuno-oncology company developing first-in-class drugs that target the DNA mismatch repair (MMR) pathway to make cancers more visible to the immune system. An attorney by training with degrees in biology, he spent nearly two decades structuring biotech deals before sitting in the chief executive's chair, with senior business development and corporate development roles at Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics and Eisai. He took the helm at NeoPhore in December 2024, right after the company closed an oversubscribed Series B round backed by Bristol Myers Squibb.